Every S-1 that BioVie, Inc. (BIVI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow BIVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIVI filings page.
BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases (Parkinson’s, Alzheimer’s, Long COVID) and advanced liver disease. It is conducting a primary securities offering of up to 16,025,641 shares of Common Stock, up to 16,025,641 Pre-funded Warrants, and up to 16,025,641 Common Warrants on a best efforts basis, with no minimum raise. Each share or Pre-funded Warrant is sold together with one Common Warrant, assumed at a combined price of $1.56, with Common Warrants exercisable at $1.95 for five years. Estimated net proceeds of about $22.7 million are intended for working capital, R&D and general corporate purposes. Recent SUNRISE-PD Phase 2b data in early Parkinson’s disease met prespecified biomarker and clinical endpoints, and a $13.1 million U.S. Department of War grant supports a Phase 2 Long COVID trial. Liver candidate BIV201 has FDA Fast Track and Orphan Drug status for ascites in cirrhosis.